Financial “hocus pocus” and the (potential) effectiveness of Prostvac VF

If readers come across a report this week suggesting that Barvarian Nordic’s Prostvac VF is likely to fail in the demonstration of effectiveness in its ongoing Phase III trial, you might want to treat that report with some caution. … READ MORE …

Prostvac Phase III trial results in mCRPC “by early 2017”

According to a Reuters report issued early this morning, the CEO of Barvarian Nordic has stated publicly that the company expects results of Phase III trials of Prostvac VF in men with metastatic, castration-resistant prostate cancer (mCRPC) by early 2017 or perhaps earlier. … READ MORE …

Other prostate cancer news: Wednesday, December 8, 2010

Other prostate cancer news out today includes:

  • An article in the Wall Street Journal about the financial motives behind intensity-modulated radiation therapy (IMRT)
  • Approval from the FDA for a Phase III pivotal trial of PROSTVAC-VF … READ MORE …